Functional and histological consequences of quinolinic and kainic acid-induced seizures on hippocampal somatostatin neurons. 1991

A Manfridi, and G L Forloni, and A Vezzani, and F Fodritto, and M G De Simoni
Istituto di Ricerche Farmacologiche, Mario Negri, Milano, Italy.

Changes in endogenous somatostatin after quinolinic and kainic acids were investigated by measuring somatostatin-like peaks by in vivo voltammetry and by assessing the distribution of somatostatin-positive neurons by immunocytochemistry. Kainic acid (0.19 nmol/0.5 microliter) or quinolinic acid (120 nmol/0.5 microliter) in doses inducing comparable electroencephalographic seizure patterns, were injected into the hippocampus of freely moving rats. Somatostatin-like peaks were measured every 6 min for 3 h by a carbon fiber electrode implanted in the proximity of the injection needle. Kainic acid kept somatostatin-like peaks significantly higher than saline from 48 min after the injection till the end of the recording. Somatostatin-like peaks were dramatically elevated by quinolinic acid, reaching a maximum of 482% 60 min after the injection. Three days later, administration of kainic acid resulted in selective degeneration of CA3 pyramidal neurons but did not affect the number of somatostatin-positive cells, while quinolinic acid induced cell loss in all pyramidal layers and complete degeneration of somatostatin-positive cells in the whole hippocampus. Thus, the quantitative difference in somatostatin release in response to doses of kainic and quinolinic acids inducing comparable electroencephalographic seizure patterns was reflected in a substantial difference in the neurodegenerative consequences. In both models, the release of somatostatin in response to seizures may be interpreted as a "defense" mechanism aimed at reducing the spread of excitation in the tissue.

UI MeSH Term Description Entries
D007608 Kainic Acid (2S-(2 alpha,3 beta,4 beta))-2-Carboxy-4-(1-methylethenyl)-3-pyrrolidineacetic acid. Ascaricide obtained from the red alga Digenea simplex. It is a potent excitatory amino acid agonist at some types of excitatory amino acid receptors and has been used to discriminate among receptor types. Like many excitatory amino acid agonists it can cause neurotoxicity and has been used experimentally for that purpose. Digenic Acid,Kainate,Acid, Digenic,Acid, Kainic
D008297 Male Males
D009474 Neurons The basic cellular units of nervous tissue. Each neuron consists of a body, an axon, and dendrites. Their purpose is to receive, conduct, and transmit impulses in the NERVOUS SYSTEM. Nerve Cells,Cell, Nerve,Cells, Nerve,Nerve Cell,Neuron
D011805 Quinolinic Acids Dicarboxylic acids with a PYRIDINE backbone. Quinolinic Acids are downstream products of the KYNURENINE pathway which metabolize amino acid TRYPTOPHAN. Acids, Quinolinic
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D003543 Cysteamine A mercaptoethylamine compound that is endogenously derived from the COENZYME A degradative pathway. The fact that cysteamine is readily transported into LYSOSOMES where it reacts with CYSTINE to form cysteine-cysteamine disulfide and CYSTEINE has led to its use in CYSTINE DEPLETING AGENTS for the treatment of CYSTINOSIS. Cysteinamine,Mercaptamine,2-Aminoethanethiol,Becaptan,Cystagon,Cysteamine Bitartrate,Cysteamine Dihydrochloride,Cysteamine Hydrobromide,Cysteamine Hydrochloride,Cysteamine Maleate (1:1),Cysteamine Tartrate,Cysteamine Tartrate (1:1),Cysteamine Tosylate,Cysteamine, 35S-Labeled,Mercamine,Mercaptoethylamine,beta-Mercaptoethylamine,2 Aminoethanethiol,35S-Labeled Cysteamine,Bitartrate, Cysteamine,Cysteamine, 35S Labeled,Dihydrochloride, Cysteamine,Hydrobromide, Cysteamine,Hydrochloride, Cysteamine,Tartrate, Cysteamine,Tosylate, Cysteamine,beta Mercaptoethylamine
D004569 Electroencephalography Recording of electric currents developed in the brain by means of electrodes applied to the scalp, to the surface of the brain, or placed within the substance of the brain. EEG,Electroencephalogram,Electroencephalograms
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D006624 Hippocampus A curved elevation of GRAY MATTER extending the entire length of the floor of the TEMPORAL HORN of the LATERAL VENTRICLE (see also TEMPORAL LOBE). The hippocampus proper, subiculum, and DENTATE GYRUS constitute the hippocampal formation. Sometimes authors include the ENTORHINAL CORTEX in the hippocampal formation. Ammon Horn,Cornu Ammonis,Hippocampal Formation,Subiculum,Ammon's Horn,Hippocampus Proper,Ammons Horn,Formation, Hippocampal,Formations, Hippocampal,Hippocampal Formations,Hippocampus Propers,Horn, Ammon,Horn, Ammon's,Proper, Hippocampus,Propers, Hippocampus,Subiculums
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

A Manfridi, and G L Forloni, and A Vezzani, and F Fodritto, and M G De Simoni
April 1986, Neuroscience,
A Manfridi, and G L Forloni, and A Vezzani, and F Fodritto, and M G De Simoni
May 2001, Brain research,
A Manfridi, and G L Forloni, and A Vezzani, and F Fodritto, and M G De Simoni
June 2018, Neurochemistry international,
A Manfridi, and G L Forloni, and A Vezzani, and F Fodritto, and M G De Simoni
June 2018, Molecular brain,
A Manfridi, and G L Forloni, and A Vezzani, and F Fodritto, and M G De Simoni
April 2001, Brain research,
A Manfridi, and G L Forloni, and A Vezzani, and F Fodritto, and M G De Simoni
October 2009, Brain research reviews,
A Manfridi, and G L Forloni, and A Vezzani, and F Fodritto, and M G De Simoni
January 1994, Peptides,
A Manfridi, and G L Forloni, and A Vezzani, and F Fodritto, and M G De Simoni
January 2016, eNeuro,
A Manfridi, and G L Forloni, and A Vezzani, and F Fodritto, and M G De Simoni
July 2013, Neurotoxicity research,
A Manfridi, and G L Forloni, and A Vezzani, and F Fodritto, and M G De Simoni
January 2001, Neuroscience letters,
Copied contents to your clipboard!